Collaborate with usWhat’s new?
Insights

Defining the future of Clinical Care.

Our industry-leading approach is paving the way for personalized, patient-centric treatments.

Publication

Evaluating The Efficacy of a Cognitive-Emotional Training Intervention in Depression

Presented at the Society for Biological Psychiatry, May 2017.

Authors:

Hoch et al.

Related subjects:

CT-152DepressionRejoynPosters & Presentations

Contact:

To request information regarding this poster, please contact medicalaffairs@clicktherapeutics.com

Recent publications

View all

01.27.2025

Schizophrenia
CT-155
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies

By Snipes et al.

01.10.2025

Prescription Digital Therapeutics

Editorial: Prescription digital therapeutics in psychiatry

By Colbert et al.

08.20.2024

CT-152
Rejoyn
Depression
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study

By Rothman et al.

04.13.2024

Prescription Digital Therapeutics
Migraine
Posters & Presentations

Migraine-specific Health Care Resource Utilization (HCRU) in the US: A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases

By Petrova et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

Comparison of Health Care Resource Utilization (HCRU) of Chronic Migraine and Other Migraine Patients: A Retrospective Claims Analysis.

By Kuka et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

US Economic Burden of Migraine: A Retrospective Claims Analysis

By Besedina et al.

04.09.2024

CT-132
Migraine
Posters & Presentations

A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Health Care Resource Utilization (HCRU), and Migraine-specific Costs of Care (P1-12.005)

By Gupta et al.

02.21.2024

CT-132
Migraine
Posters & Presentations

Efficacy of Recruitment Techniques for a Decentralized Trial of a Digital Therapeutic for Migraine

By Colbert et al.

09.06.2023

Schizophrenia
Prescription Digital Therapeutics
Posters & Presentations

A Pilot Study to Assess if Patients With Schizophrenia can Form a Working Alliance With a Digital Therapeutic

By Campellone et al.

06.15.2023

Migraine
Posters & Presentations
CT-132

Current Migraine Headache Treatment Characteristics in a Nationally Representative Sample of U.S. Adults

By Gupta et al.

01.27.2025

Schizophrenia
CT-155
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Establishment and Maintenance of a Digital Therapeutic Alliance in People Living With Negative Symptoms of Schizophrenia: Two Exploratory Single-Arm Studies

By Snipes et al.

01.10.2025

Prescription Digital Therapeutics

Editorial: Prescription digital therapeutics in psychiatry

By Colbert et al.

08.20.2024

CT-152
Rejoyn
Depression
Prescription Digital Therapeutics
Peer-reviewed Manuscripts

Evaluating the Efficacy of a Digital Therapeutic (CT-152) as an Adjunct to Antidepressant Treatment in Adults With Major Depressive Disorder: Protocol for the MIRAI Remote Study

By Rothman et al.

04.13.2024

Prescription Digital Therapeutics
Migraine
Posters & Presentations

Migraine-specific Health Care Resource Utilization (HCRU) in the US: A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases

By Petrova et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

Comparison of Health Care Resource Utilization (HCRU) of Chronic Migraine and Other Migraine Patients: A Retrospective Claims Analysis.

By Kuka et al.

04.13.2024

Migraine
CT-132
Posters & Presentations

US Economic Burden of Migraine: A Retrospective Claims Analysis

By Besedina et al.

04.09.2024

CT-132
Migraine
Posters & Presentations

A Retrospective Cohort Study of Recent Large Multiple Commercial Payer Databases to Elucidate Migraine-specific Health Care Resource Utilization (HCRU), and Migraine-specific Costs of Care (P1-12.005)

By Gupta et al.

02.21.2024

CT-132
Migraine
Posters & Presentations

Efficacy of Recruitment Techniques for a Decentralized Trial of a Digital Therapeutic for Migraine

By Colbert et al.

09.06.2023

Schizophrenia
Prescription Digital Therapeutics
Posters & Presentations

A Pilot Study to Assess if Patients With Schizophrenia can Form a Working Alliance With a Digital Therapeutic

By Campellone et al.

06.15.2023

Migraine
Posters & Presentations
CT-132

Current Migraine Headache Treatment Characteristics in a Nationally Representative Sample of U.S. Adults

By Gupta et al.

View all

Discover our products

CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Cleared
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

Regulatory Review
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 3: Pivotal
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery
CT-152

CT-152

Rejoyn

Indication

Major Depressive Disorder (MDD)

Collaborator

Otsuka Pharmaceutical

Phase

Launch
AspyreRx

AspyreRx

AspyreRx™

Indication

Type 2 Diabetes

Collaborator

Phase

FDA Cleared
CT-132

CT-132

Indication

Episodic Migraine

Collaborator

Phase

Regulatory Review
CT-155

CT-155

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 3: Pivotal
CT-156

CT-156

Indication

Schizophrenia

Collaborator

Boehringer Ingelheim

Phase

Phase 2: Dev/Pilot
CT-102

CT-102

Indication

Opioid Use Disorder (OUD)

Collaborator

Phase

Phase 2: Dev/Pilot
CT-133

CT-133

Indication

Multiple Sclerosis (MS)

Collaborator

Phase

Phase 1: Discovery
CT-171

CT-171

Indication

Atopic Dermatitis

Collaborator

Phase

Phase 1: Discovery
CT-181

CT-181

Indication

Obesity

Collaborator

Phase

Phase 1: Discovery
CT-191

CT-191

Indication

Oncology

Collaborator

Phase

Phase 1: Discovery
CT-141

CT-141

Clickadian™

Indication

Insomnia

Collaborator

Phase

Phase 1: Discovery
CT-111

CT-111

Clickheart™

Indication

Acute Coronary Syndrome

Collaborator

Phase

Phase 1: Discovery

Stay up to date with news and updates